Date: 2014-01-09
Type of information: Collaboration agreement
Compound: process development and cGMP production
Company: Lonza (Switzerland) Index Ventures (Switzerland)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 9, 2014, Lonza, and the venture capital investment firm Index Ventures have announced an exclusive agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor. Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.
Financial terms:
Latest news:
